User:Aphis Marta/sandbox/iqosrec

'''This text was revised here in sandbox to provide a recommendations for how to shorten the IQOS section at Electric_smoking_system, for which I am a WP:PAID editor. I don't edit that page directly, only the talk space. Because the IQOS section is extremely long compared to the other product sections, the edits I expect to suggest are significant, and so I am editing directly in my own user sandbox. This page is meant to make it easier to know which changes I'm recommending and why.'''

IQOS
IQOS is marketed by Philip Morris International under the Marlboro and Parliament brands. Its electronic components consist of a charger about the size of a mobile phone and a holder shaped like a pen. The disposable tobacco stick is called a HeatStick or HEET and looks similar to a short cigarette, though the tobacco is processed differently. The stick must be inserted into the holder, which then heats it to temperatures up to 350 °C.

Initially launched in 2014 in Nagoya, Japan and Milan, Italy, IQOS is being gradually rolled out to other countries. As of April 2019, IQOS was available in around 44 countries. In October 2018, the IQOS 3 was launched as well as the IQOS 3 Multi, which is capable of multiple consecutive uses.

The emissions generated by IQOS contains some of the harmful constituents in tobacco cigarette smoke, though the levels are on average lower than those found in cigarette smoke. According to government reports published in the Netherlands, England, and Germany, the IQOS product is likely less toxic or harmful than traditional cigarettes.

PMI submitted applications to the FDA for IQOS to be authorized as a modified risk tobacco product on December 5, 2016. An advisory panel made recommendations about the application to the FDA in January 2018, though the review for these applications is still ongoing. In March 2017, PMI submitted a premarket tobacco product application for IQOS. The FDA announced permission for the sale of IQOS in the US on April 30, 2019, staing that "authorizing these products for the U.S. market is appropriate for the protection of the public health." This permission also requires the company to follow strict marketing restrictions.